This is Aurobindo Pharma’s first share buyback in nearly two years. Back in August 2024, the company had announced the repurchase of 51.36 lakh equity shares at a price of ₹1,460 apiece. The drugmaker had spent ₹750 crore for this buyback, which was also carried out via the tender offer route.
